Adjuvant early breast cancer systemic therapies according to daily used technologies.

Details

Serval ID
serval:BIB_06C3CDD95730
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Adjuvant early breast cancer systemic therapies according to daily used technologies.
Journal
Critical Reviews In Oncology/hematology
Author(s)
Jacot W., Gutowski M., Azria D., Romieu G.
ISSN
1879-0461 (Electronic)
ISSN-L
1040-8428
Publication state
Published
Issued date
2012
Volume
82
Number
3
Pages
361-369
Language
english
Notes
Publication types: Journal Article ; Review
Abstract
Prognosis of early breast cancer patients is significantly improved with the use of adjuvant therapies. Various guidelines have been proposed to select patients who will derive the most benefit from such treatments. However, classifications have limited usefulness in subsets of patients such as those with node negative breast cancer. The 2007 St. Paul de Vence Clinical Practice Recommendations proposed to consider adjuvant therapy in accordance with the 10-year relapse-free survival reduction estimated by Adjuvant! Online. However, many limitations remain regarding the use of Adjuvant! Online. Among them, adverse prognostic and/or predictive factors such as vascular invasion, mitotic activity, progesterone receptor negativity, and HER-2 expression are not incorporated in the routine clinical decision process. Our group has therefore issued guidelines based on the consideration of both Adjuvant! Online calculations and the prognostic and/or predictive effects of these markers. In addition, web-accessible comprehensive tables summarizing these recommendations are provided.
Keywords
Antineoplastic Agents/administration & dosage, Antineoplastic Agents/therapeutic use, Breast Neoplasms/drug therapy, Breast Neoplasms/pathology, Cell Proliferation/drug effects, Chemotherapy, Adjuvant, Disease-Free Survival, Drug Administration Schedule, Female, Gene Expression/drug effects, Humans, Internet, Practice Guidelines as Topic, Predictive Value of Tests, Prognosis, Receptor, erbB-2/genetics, Receptor, erbB-2/metabolism, Receptors, Progesterone/genetics, Receptors, Progesterone/metabolism, Secondary Prevention
Pubmed
Web of science
Create date
08/02/2012 8:33
Last modification date
20/08/2019 12:29
Usage data